CA2494801A1 - Composition medicamenteuse contenant un inhibiteur de hmg-coa reductase - Google Patents

Composition medicamenteuse contenant un inhibiteur de hmg-coa reductase Download PDF

Info

Publication number
CA2494801A1
CA2494801A1 CA002494801A CA2494801A CA2494801A1 CA 2494801 A1 CA2494801 A1 CA 2494801A1 CA 002494801 A CA002494801 A CA 002494801A CA 2494801 A CA2494801 A CA 2494801A CA 2494801 A1 CA2494801 A1 CA 2494801A1
Authority
CA
Canada
Prior art keywords
nitric oxide
hmg
vascular endothelial
coa reductase
oryzanol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002494801A
Other languages
English (en)
Inventor
Tatsuhito Kondo
Ikuo Takagi
Masato Nakayama
Yasuhiro Torizumi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sankyo Co Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2494801A1 publication Critical patent/CA2494801A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A61K31/51—Thiamines, e.g. vitamin B1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne la recherche d'une composition médicamenteuse permettant d'activer la synthèse d'oxyde d'azote de l'endothélium vasculaire et/ou de maintenir ou d'augmenter la concentration d'oxyde d'azote de l'endothélium vasculaire dans le sang, ou bien d'une composition médicamenteuse permettant d'augmenter les lipides sanguins. A cet effet, on a mis au point une composition médicamenteuse qui contient un inhibiteur de HMG-CoA réductase, du .gamma.-oryzanol et/ou des thiamines.
CA002494801A 2002-08-02 2003-08-01 Composition medicamenteuse contenant un inhibiteur de hmg-coa reductase Abandoned CA2494801A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2002225979 2002-08-02
JP2002-225979 2002-08-02
JP2002260719 2002-09-06
JP2002-260719 2002-09-06
PCT/JP2003/009835 WO2004012740A1 (fr) 2002-08-02 2003-08-01 Composition medicamenteuse contenant un inhibiteur de hmg-coa reductase

Publications (1)

Publication Number Publication Date
CA2494801A1 true CA2494801A1 (fr) 2004-02-12

Family

ID=31497621

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002494801A Abandoned CA2494801A1 (fr) 2002-08-02 2003-08-01 Composition medicamenteuse contenant un inhibiteur de hmg-coa reductase

Country Status (6)

Country Link
JP (1) JP2010150288A (fr)
AU (1) AU2003252358A1 (fr)
CA (1) CA2494801A1 (fr)
HK (1) HK1077230A1 (fr)
TW (1) TW200409635A (fr)
WO (1) WO2004012740A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3875092A4 (fr) * 2018-11-02 2021-12-22 Kyungpook National University Industry-Academic Cooperation Foundation Composition de prévention ou de traitement de la dégénérescence maculaire

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54135740A (en) * 1978-04-13 1979-10-22 Otsuka Nobuhiro Method of dissolving oryznol to greases or their products
CA2251972A1 (fr) * 1996-04-17 1997-10-23 Merck & Co., Inc. Therapie combinatoire pour reduire les risques associes a une maladie cardiovasculaire
NZ520176A (en) * 1997-07-31 2005-02-25 Kos Life Sciences Inc Combinations of HMG-CoA reductase inhibitors and nicotinic acid compounds and methods for treating hyperlipidemia once a day at night
JP3597437B2 (ja) * 2000-02-10 2004-12-08 日清オイリオグループ株式会社 血中脂質改善機能を有する食用油脂
WO2002034261A1 (fr) * 2000-10-23 2002-05-02 Sankyo Company, Limited Compositions hypocholesterolemiantes

Also Published As

Publication number Publication date
WO2004012740A1 (fr) 2004-02-12
AU2003252358A1 (en) 2004-02-23
JP2010150288A (ja) 2010-07-08
TW200409635A (en) 2004-06-16
HK1077230A1 (en) 2006-02-10

Similar Documents

Publication Publication Date Title
ES2334672T3 (es) Composicion farmaceutica que comprende un combinacion de metformina y una estatina.
US20050187204A1 (en) Medicinal composition for lowering blood lipid level
JP2013035871A (ja) 炎症性肺疾患の治療のためのＨＭＧ−ＣｏＡレダクターゼインヒビターとホスホジエステラーゼ４インヒビターとの組合せ物
US20150272944A1 (en) Novel triglyceride reducing agent
KR20010093845A (ko) 피브레이트와 세리바스타틴의 복합제제
CA2679416A1 (fr) Polytherapie, composition et methodes de traitement de troubles cardiovasculaires
US20050182036A1 (en) Medicinal composition containing an HMG-CoA reductase inhibitor
CA2492781A1 (fr) Composition medicale pour reduire le taux de lipides sanguins ou le taux d'homocysteine sanguine
JP4949661B2 (ja) ＨＭＧ−ＣｏＡリダクターゼ阻害剤とグルタチオンを含有する医薬組成物
US20080070938A1 (en) Medicinal composition for mitigating blood lipid or lowering blood homocysteine
US6916849B2 (en) Compositions for improving lipid content in the blood
JP2003503342A (ja) ＭＴＰ阻害剤とＨＭＧ−ＣｏＡ還元酵素阻害剤との組み合わせ並びに薬剤におけるその使用
JP2002518448A (ja) 高血中コレステロールを治療する組成物および方法
CA2494801A1 (fr) Composition medicamenteuse contenant un inhibiteur de hmg-coa reductase
JP4607436B2 (ja) ＨＭＧ−ＣｏＡリダクターゼ阻害剤を含有する医薬組成物
US20040023919A1 (en) Blood lipid ameliorant composition
JP4896501B2 (ja) 血中遊離脂肪酸低下作用を有する医薬組成物
US20030216357A1 (en) Compositions for improving lipid content in the blood
CA2494916A1 (fr) Composition medicale abaissant le taux de lipides sanguins
AU2001282541B2 (en) Medicinal compositions
JP4454985B2 (ja) 血液脂質を低下させるための医薬組成物
JP4611622B2 (ja) 血中脂質改善又は血中ホモシステイン低下のための医薬組成物
CN100415235C (zh) 含有HMG-CoA还原酶抑制剂的药物组合物
US20040186163A1 (en) Novel combination
JPH1081633A (ja) 医薬組成物

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead